Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2024 08:15 ET | Source: Senti Biosciences, Inc.

Senti Bio to Participate in Upcoming Investor Conferences

Senti Bio will participate in two upcoming investor conferences in September.
August 13, 2024 16:05 ET | Source: Senti Biosciences, Inc.

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...
May 09, 2024 16:05 ET | Source: Senti Biosciences, Inc.

Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights

Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.
June 15, 2020 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors

HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by...
December 11, 2019 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson

HOUSTON, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The...